Jul 22, 2021 9:25am EDT LIXTE BIOTECHNOLOGY COMMENTS ON REPORT THAT ITS PP2A INHIBITOR LB-100 COMBINED WITH ANOTHER INVESTIGATIONAL AGENT STIMULATES BONE GROWTH IN MODELS OF DWARFISM
Jul 13, 2021 9:25am EDT Lixte Biotechnology Comments on Outside Research Citing LB-100’s PP2A Inhibition as a Potential Therapeutic Strategy for Triple-Negative Breast Cancer
Jul 07, 2021 9:35am EDT Lixte Biotechnology to Present its Drug Development Pipeline for Cancer Treatment at The MoneyShow Virtual Expo on July 14, 2021
Jun 02, 2021 9:35am EDT Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer
May 12, 2021 9:35am EDT LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THE APPOINTMENT OF REGINA BROWN TO ITS BOARD OF DIRECTORS
May 04, 2021 4:30pm EDT Lixte Biotechnology to Present Key Advantages of Novel Cancer Drug Candidate LB-100 at the Sidoti Virtual Microcap Conference on May 20
Apr 28, 2021 9:35am EDT Lixte Biotechnology to Discuss Pipeline of Clinical Investigations for Four Cancer Targets at the Benzinga Global Small Cap Conference Being Held May 13-14
Apr 13, 2021 9:35am EDT Lixte Biotechnology Holdings, Inc. Announces the Appointment of Gil N Schwartzberg to its Board of Directors
Mar 17, 2021 9:35am EDT Lixte Biotechnology to Present Its Novel Product Candidate for Targeted Cancer Therapy at the Benzinga Biotech Small Cap Conference on March 24
Mar 03, 2021 9:35am EST Lixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital Conference
